The top 5 OncLive TV videos of the week.
News|Videos|November 11, 2025
Updated Results from the EDGE-Gastric Arm A1 Study
Author(s)Yelena Y. Janjigian, MD
Summarize long-term results from the phase 2 EDGE-Gastric Arm A1 study evaluating domvanalimab (anti-TIGIT) + zimberelimab (anti-PD-1) + FOLFOX as first-line therapy for advanced HER2-negative gastric, GEJ, or esophageal adenocarcinoma. Key data shown include ORR, PFS, OS, and safety outcomes, demonstrating encouraging clinical activity and manageable toxicity, along with context regarding the ongoing phase 3 STAR-221 trial.
Advertisement
Advertisement
Related to this article
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.
Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 10/4/2026
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
4
VIR-5500 Receives FDA Fast Track Designation in mCRPC
5